P38 MAP kinase inhibitors: Evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes

Current Topics in Medicinal Chemistry

Volumn 5, Issue 10, 2005, Pages 987-1003

  Natarajan, Swaminathan R ^a   Doherty, James B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; IMIDAZOLE DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MORPHOLINE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; NEW DRUG; PIPERAZINE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINONE DERIVATIVE; QUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; INFLAMMATION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; IMIDAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDAZINES; PYRIMIDINES; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27744530913     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054985876     Document Type: Review

References (25)

1. Lee, J. C.; Laydon, J. T.; McDonell, P. S.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739.
2. Han, J.; Lee, J. -D.; Bibbs, L.; Ulevitch, R. J. A MAP Kinase targetted by endotoxin and hyperosmolarity in mammalian cells Science 1994, 265, 808.
3. Rouse, J.; Cohen, P.; Trigon, S.; Morange, M.; Alonso-Llamazares, A.; Zamanillo, D.; Hunt, T.; Nebreda, A. R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock protein Cell 1994, 78, 1027.
4. Lee, J. C.; Badger, A. M.; Griswald, D. E.; Dunnington, D.; Truenh, A.; Votta, B.; White, J. R.; Young, P. R.; Bender, P. E. Annals New York Academy of Sciences 1993, 896, 149.
5. a) Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine supppresive binding protein / p38 kinase in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol. Exp. Ther. 1996, 279, 1453.
6. b) Boehm, J. C.; Smietana, J. M.; Sorensen, M. E.; Garigipatti, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. L. 1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency. J. Med. Chem. 1996, 39, 3929.
7. De Laszlo, S. E.; Visco, D.; Agarwal, L.; Chang, L.; Chin, J.; Croft, G.; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.; Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; MacCoss, M.; Mantlo, N.; O'Neill, E. A.; Orevillo, C.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; Widmer, R. W.; O'Keefe, S. J. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 1998, 8, 2689.
8. a) Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Ngyuen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Danheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neil, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolondo, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and synthesis of potent, selective and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen activated protein kinase. J. Med. Chem. 1999, 42, 2180.
9. b) Selnick, H. G.; Claremon, D. A.; Liverton, N. J. Intl. Patent, 1997, WO 9712876.
10. O'Keefe, S. J.; Zaller, D. M.; Doherty, J. B. Unpublished results,
11. Biftu, T.; Colletti, S. L.; McIntyre, C. J.; Schmatz, D. M.; Feng, D. D.; Doherty, J. B.; Liang, G. -B.; Liverton, N. J.; Beresis, R.; Berger, R.; Claremon, D. A.; Kovacs, E. W.; Qian, X. Intl. Patent, 2003, WO 03000682.
12. a) Bemis, G. W.; Salituro, F. G.; Duffy, J. P.; Cochran, J. E.; Harrington, E. M.; Murcko, M. A.; Wilson, K. P.; Su, M.; Galullo, V. P. Intl. Patent, 1998, WO 98/27098.
13. b) Salituro, F.; Bemis, G.; Cochran, J. Intl. Patent, 1999, WO 99/64400.
14. Bemis, G. W.; Salituro, F. G.; Duffy, J. P.; Harrington, E. M. US Patent, 2000, 6, 147,080.
15. Salituro, F. G. 27th National Medicinal Chemistry Symposium, Kansas City, MO, June 13-17, 2000.
16. Resonance structure of VX-745 (26) and its reduced con-gener 24; the aromatic resonance form is thought to contribute substantially to observed properties of these molecules.
17. Natarajan, S. R.; Wisnoski, D. D.; Singh, S. B.; Stelmach, J. E.; O'Neill, E. A.; Schwartz, C. D.; Thompson, C. M.; Fitzgerald, C. E.; O'keefe, S. J.; Kumar, S.; Hop, C. E. C. A.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. p38 MAP kinase inhibitors. Part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg. Med. Chem. Lett. 2003, 13, 273.
18. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, P.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; So, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423.
19. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP Kinases. Structure 1998, 6, 1117.
20. Nam, K.; Natarajan, S. R.; Doherty, J. B. Unpublished Results 2005. Partial Charges and dipole moments were derived from the geometry optimization of each scaffold (represented by 25 and 27) with the Hartree-Fock method using 6-31G** basis set.
21. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Str. Biol. 2003, 10, 764.
22. Liu, L.; Stelmach, J. E.; Natarajan, S. R.; Chen, M. -H.; Singh, S. B.; Schwartz, C. D.; Fitzgerald, C. E.; O'Keefe, S. J.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. SAR of 3,4-Dihydro[3,2-d]pyrimidone p38 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3979.
23. Natarajan, S. R.; Wisnoski, D. W.; O'Keefe, S. J.; Zaller, D. M.; Doherty, J. B. Unpublished results, 2002.
24. Stelmach, J. E.; Liu, L.; Patel, S. B.; Pivnichny, J. V.; Scapin, G.; Singh, S. B.; Hop, C. E. C. A.; Wang, Z.; Strauss, J. R.; Cameron, P. M.; Nichols, E. A.; O'keefe, S. J.; O'neill, E. A.; Schmatz, D. M.; Schwartz, C. D.; Thompson, C. M.; Zaller, D. M.; Doherty, J. B. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP Kinase. Bioorg. Med. Chem. Lett. 2003, 13, 277.
25. Hunt, J. A.; Kallashi, F.; Ruzek, R. D.; Sinclair, P. J.; Ita, I.; McCormick, S. X.; Pivnichny, J. V.; Hop, C. E. C. A.; Kumar, S.; Wang, Z.; O'Keefe, S. J.; O'Neill, E. A.; Porter, G.; Thompson, J. E.; Woods, A.; Zaller, D. M.; Doherty, J. B. P38 inhibitors: piperidine and 4-aminopiperidine substituted naphthyridinones, quinolinones and dihydroquinazolinones. Bioorg. Med. Chem. Lett. 2003, 13, 467.